PHAT icon

Phathom Pharmaceuticals

4.15 USD
+0.04
0.97%
At close Apr 28, 4:00 PM EDT
After hours
4.18
+0.03
0.72%
1 day
0.97%
5 days
3.75%
1 month
-37.12%
3 months
-33.60%
6 months
-76.12%
Year to date
-43.38%
1 year
-55.61%
5 years
-88.96%
10 years
-83.13%
 

About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Employees: 427

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

131% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 26

64% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 22

8% more funds holding

Funds holding: 133 [Q3] → 144 (+11) [Q4]

8.86% less ownership

Funds ownership: 106.36% [Q3] → 97.51% (-8.86%) [Q4]

42% less funds holding in top 10

Funds holding in top 10: 12 [Q3] → 7 (-5) [Q4]

59% less capital invested

Capital invested by funds: $1.31B [Q3] → $541M (-$771M) [Q4]

91% less call options, than puts

Call options by funds: $455K | Put options by funds: $5.2M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$10
141%
upside
Avg. target
$22
430%
upside
High target
$28
575%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Needham
Joseph Stringer
24% 1-year accuracy
27 / 112 met price target
575%upside
$28
Buy
Reiterated
21 Apr 2025
Goldman Sachs
Paul Choi
67% 1-year accuracy
10 / 15 met price target
141%upside
$10
Neutral
Maintained
17 Apr 2025
HC Wainwright & Co.
Matthew Caufield
23% 1-year accuracy
16 / 69 met price target
575%upside
$28
Buy
Reiterated
7 Mar 2025

Financial journalist opinion

Based on 8 articles about PHAT published over the past 30 days

Neutral
GlobeNewsWire
15 hours ago
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present real-world data for its first-in-class treatment VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) being held May 3–6, 2025, in San Diego, CA. VOQUEZNA is the first and only treatment of its kind approved by the U.S. Food and Drug Administration for use in adults for the relief of heartburn associated with Non-Erosive GERD and for the treatment of all severities of Erosive Esophagitis (EE), commonly referred to as Erosive GERD, and relief of related heartburn.
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
Neutral
GlobeNewsWire
5 days ago
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update.
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
Neutral
Business Wire
1 week ago
Frazier Life Sciences Appoints Aditya Kohli to Partner
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ: HLVX, IPO in 2022), Phathom Pharmaceuticals (NASDAQ: PHAT, IPO in 2019), and Scout Bio (acquired by Ceva Santé Animale). He previously acted.
Frazier Life Sciences Appoints Aditya Kohli to Partner
Neutral
GlobeNewsWire
1 week ago
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
Neutral
GlobeNewsWire
3 weeks ago
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET.
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Neutral
GlobeNewsWire
3 weeks ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Steven Basta as President and Chief Executive Officer, the Company's Board of Directors has approved the grant of inducement awards.
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
3 weeks ago
Phathom Pharmaceuticals Announces Leadership Succession
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for personal reasons.
Phathom Pharmaceuticals Announces Leadership Succession
Neutral
GlobeNewsWire
4 weeks ago
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaign VOQUEZNA is a potassium competitive acid blocker (PCAB), the first and only FDA-approved treatment of its kind for both types of GERD 1 A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J.
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
Neutral
Seeking Alpha
1 month ago
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham Annabel Samimy - Stifel Kristen Kluska - Cantor Fitzgerald Paul Choi - Goldman Sachs Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call.
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates
Charts implemented using Lightweight Charts™